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AbstrAct
Background 10%–15% of early- stage colon cancers 
harbour either deficient mismatch repair (dMMR), 
microsatellite instability high (MSI- H) or POLE exonuclease 
domain mutations, and are characterised by high tumour 
mutational burden and increased lymphocytic infiltrate. 
Metastatic dMMR colon cancers are highly sensitive to 
immune checkpoint inhibition, and recent data show 
POLE- mutant tumours are similarly responsive. We are 
conducting a phase III randomised trial to determine if the 
addition of the anti- PD- L1 antibody avelumab following 
adjuvant chemotherapy improves disease- free survival 
(DFS) in patients with stage III dMMR/MSI- H or POLE 
mutant colon cancer and is a cost- effective approach for 
the UK National Health Service (NHS).
Methods We are recruiting patients with completely 
resected, stage III colon cancer confirmed to have dMMR/
MSI- H, locally or POLE exonuclease domain mutation on 
central testing. Eligible patients are randomised in a 1:1 
ratio to standard fluoropyrimidine- based chemotherapy 
(capecitabine, oxaliplatin for 12 weeks or capecitabine 
for 24 weeks) or chemotherapy, followed by avelumab 
(10 mg/kg, 2 weekly for 24 weeks). Stratification is by 
chemotherapy received and MMR/MSI- H status. The 
primary endpoint is DFS. Secondary endpoints include 
overall survival, toxicity, quality of life and health resource 
use. The 3- year DFS rate in the control arm is expected 
to be ~75%. Avelumab is expected to improve the 3- year 
DFS rate by 12% (ie, 87%). Target accrual is 402 patients, 
which provides 80% power to detect an HR of 0.48 for DFS 
at a two- sided alpha of 0.05. This national, multicentre 
phase III trial is sponsored by the Royal Marsden NHS 
Foundation Trust and it is anticipated that approximately 
40 centres in the UK will participate. This study opened to 
recruitment in August 2018.
Trial registration number NCT03827044
InTroduCTIon
Colorectal cancer (CRC) is the third most 
common cancer, with a worldwide annual 
Key questions
What is already known about this subject?
 ► Fluoropyrimidine- based adjuvant chemotherapy fol-
lowing surgery is the current standard of care for 
stage III colon cancer.
 ► Immune checkpoint therapy is effective in the treat-
ment of deficient mismatch repair (dMMR)/micro-
satellite instability high (MSI- H) colorectal cancer 
(CRC) in the advanced setting. POLE mutant CRC 
(mCRC) has also been proposed as a type of mCRC, 
which is also responsive to immunotherapy.
 ► To our knowledge, there is no mature randomised 
clinical data to support the use of immune check-
point inhibitors in the curative setting such as 
dMMR/MSI- H or POLE mutant stage III colon.
What does this study add?
 ► The POLEM trial is an open- label, multicentre, ran-
domised, phase III study testing the efficacy of the 
immune checkpoint inhibitor avelumab (anti- PD- L1) 
following standard adjuvant chemotherapy in 
dMMR/MSI- H or POLE mutant stage III colon cancer.
 ► Eligible patients are randomly allocated to receive 
investigator choice chemotherapy (12 weeks of 
capecitabine, oxaliplatin or 24 weeks capecitabine), 
followed by avelumab for 24 weeks or chemother-
apy alone.
 ► The recruitment aim is 402 patients and the study is 
currently open in the UK with potential for interna-
tional collaboration.
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Key questions
How might this impact on clinical practice?
 ► The results from this study will determine whether immune check-
point therapy such as avelumab (anti- PD- L1) should be added to 
standard adjuvant chemotherapy in deficient mismatch repair/mi-
crosatellite instability high or POLE mutant stage III colon cancer.
incidence of over 1.2 million cases and a mortality rate of 
approximately 50%.1 2 Around, 80% of patients with CRC 
have localised and resectable disease at diagnosis, with 
5- year survival varying from 90% in stage I to 70%–80% 
in stage II and 40%–65% in stage III disease. The risk 
of recurrence also depends on the pathological stage of 
the primary tumour (30% in stage II and 50% in stage 
III) and is higher within the first 2 years after surgery.3 
The treatment of resectable disease is surgery ±adjuvant 
fluoropyrimidine- based chemotherapy depending on the 
pathological stage. To improve these survival statistics, 
there is a need for new treatments and predictive and 
prognostic biomarkers that can identify patients who are 
most likely to benefit.
The DNA mismatch repair (MMR) machinery is essen-
tial for maintenance of genomic integrity. Defects in DNA 
MMR can occur either at the germline (Lynch syndrome) 
or epigenetic level.4 Deficiency MMR (dMMR) results in 
a failure to repair DNA replication errors, manifest as 
an increased frequency of somatic mutations5—typically 
10 to 100- foldgreater than MMR proficient/microsatel-
lite stable (pMMR/MSS) CRC.6–8 dMMR/microsatellite 
instability high (MSI- H) is more common among stage 
II (20%) than stage III (12%) and less frequent among 
stage IV CRC (4%).9 10 dMMR/MSI- H CRCs tend to be 
right sided, high grade and have mucinous phenotypes 
and prominent numbers of tumour- infiltrating lympho-
cytes.11 The mean disease- free survival (DFS) of stage III 
dMMR/MSI- H CRC is around 73% and 5- year overall 
survival (OS) is 83%.12
The management of metastatic dMMR/MSI- H CRC 
has recently been transformed by clinical data demon-
strating remarkable clinical benefit of PD-1 inhibitors in 
this setting.13–16 Mechanistically, this is thought to relate 
to the high number of neoantigens in these tumours,13 
and the reversal of the strong upregulation of immune 
checkpoints (eg, PD-1, PD- L1, cytotoxic T lymphocytes- 
associated protein-4 (CTLA-4), LAG-3 and IDO) which 
may overcome a phenomenon referred to as ‘adaptive 
immune resistance’. These data, together with evidence 
that increased PD- L1 expression is associated with poor 
prognosis in stage III CRC,15 provide a compelling ratio-
nale for testing the efficacy of immune checkpoint inhibi-
tion in stage III dMMR/MSI- H CRC.
Importantly, National Institute for Health and Care 
Excellence (NICE, UK) guidance from 2017 recom-
mends MMR or microsatellite instability testing should 
be undertaken for all patients with CRC, when first 
diagnosed, using immunohistochemistry or PCR for 
Lynch syndrome.17
The proofreading exonuclease activity intrinsic to 
the replicative DNA polymerases POLE and POLD1 is 
critical in the maintenance of DNA replication fidelity 
and prevention of mutagenesis. The relevance of this 
to human cancer was confirmed by the demonstration 
that germline mutations in the POLE and POLD1 exonu-
clease domains cause intestinal polyposis and early- onset 
cancer,18 and the demonstration of somatic POLE exonu-
clease domain mutations in CRC by The Cancer Genome 
Atlas (TCGA).8 In the TCGA study, POLE- mutant cancers 
were found to have and exceptionally high number 
of somatic mutations (over 50 per 106 bases), in the 
absence of MMR defects.18 19 Further analysis of these 
cases revealed higher expression of immune checkpoints, 
including PD- L1 and PD- L2, than either dMMR/MSI- H 
or pMMR/MSS cancers.20 Similarly, POLE mutant cancers 
also showed higher expression of T cell markers such as 
CD8A, PD-1 and CTLA-4 suggesting the presence of a 
pre- existing T cell infiltrate.20
TCGA data suggest that POLE exonuclease domain 
mutant somatic mutations are in the range of 1%–3% of 
patients,8 however, published and unpublished data21 show 
that in the under 50 years the incidence of POLE muta-
tions is 8%–10%. While somatic POLE mutation portends 
reduced risk of relapse in stage II CRC, the association 
with favourable prognosis appears to be lost in stage III 
disease.20 22 These tumours with a so- called ‘ultramutated’ 
phenotype may be very responsive to checkpoint inhibi-
tion for similar reasons to those thought to underlie the 
increased sensitivity of dMMR cases.18 Indeed, a recent 
case report suggests this is the case.23
The aim of this study is to determine whether dMMR/
MSI- H and/or POLE exonuclease domain mutant stage 
III colon cancer patients gain clinical benefit (ie, improve-
ment in disease- free and OS) from PD- L1 inhibition after 
standard fluoropyrimidine- based adjuvant chemotherapy 
and to examine whether this is a cost- effective approach 
for the National Health Service.
Avelumab is a humanised monoclonal antibody, which 
binds PD- L1 and blocks the interaction between PD- L1 
and PD-1. This removes the suppressive effects of PD- L1 
on anti- tumour CD8 +T cells, resulting in the restoration 
of cytotoxic T cell response.
The rationale of giving avelumab after standard adju-
vant chemotherapy to this well- defined, molecularly 
selected, group is based on the observation that dMMR/
MSI- H and POLE exonuclease domain mutant CRCs have 
a highly and ultramutated genetic profile, respectively, 
thus leading to a high number of neoantigens with asso-
ciated over expression of immune checkpoint- related 
proteins. This profile is expected to be highly responsive 
to checkpoint inhibition as suggested by data of PD-1 
inhibitors in dMMR/MSI- H metastatic CRC.14–16
If this study meets the primary endpoint, using 
avelumab in the adjuvant setting following standard 
chemotherapy would become the standard of care for 
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Table 1 POLEM trial inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. Male or female subjects aged ≥18 years
2. ECOG PS 0/1
3. Histologically proven, stage III (ie, any T, N1 or N2, 
M0) adenocarcinoma of the colon (as defined by the 
presence of the inferior pole of the tumour above 
the peritoneal reflection, ie, at least 15 cm from the 
anal margin).
4. Fully surgically resected tumour with clear resection 
margins (ie, >1 mm).
5. Locally confirmed defective mismatch repair 
(MMR) tumour (as defined by the lack of staining 
on either preoperative biopsy samples or resection 
specimens of at least one of the following proteins: 
MLH1, MSH2, MSH6, PMS2), locally confirmed 
microsatellite instability high, or centrally confirmed 
POLE exonuclease domain mutated tumour (in 
subjects <50 years old with locally confirmed 
proficient MMR tumours).
6. Absence of metastases as shown by postoperative 
CT and/or MRI scan.
7. Absence of major postoperative complications 
or other clinical conditions that, in the opinion of 
the investigator, would contraindicate adjuvant 
chemotherapy.
8. Adequate haematological function defined by 
absolute neutrophil count ≥1.5×109/L, platelet 
count ≥100×109/L and haemoglobin ≥9 g/L (blood 
transfusion before recruitment is allowed).
9. Adequate hepatic function defined by a total 
bilirubin level ≤1.5× the upper limit of normal (ULN) 
range and AST and ALT levels ≤2.5 × ULN.
10. Adequate renal function defined by an estimated 
creatinine clearance ≥30 mL/min according to 
the Cockcroft- Gault formula (or local institutional 
standard method).
11. Negative serum or urine pregnancy test at 
screening for women of childbearing potential.
12. Fertile men and women must agree to take highly 
effective contraceptive precautions during, and for 
6 months after the last dose of chemotherapy or for 
30 days after the last dose of avelumab.
1. Rectal tumours (as defined by the presence of the inferior pole of the tumour 
below the peritoneal reflection, ie,<15 cm from the anal margin).
2. Inability to start adjuvant chemotherapy within 12 weeks after surgery.
3. Administration of neoadjuvant systemic chemotherapy or radiotherapy before 
surgical resection of colon cancer.
4. Prior organ transplantation, including allogeneic stem- cell transplantation.
5. Significant acute or chronic infections including, among others:
 – Positive test for HIV or known AIDS.
 – Positive test for Hepatitis B (HBV) surface antigen or anti- HCV antibody and 
confirmatory Hepatitis C (HCV) RNA test.
6. Active autoimmune disease that might deteriorate when receiving an 
immunostimulatory agent:
 – Subjects with diabetes type I, vitiligo, psoriasis, hypothyroid or hyperthyroid 
disease not requiring immunosuppressive treatment are eligible.
 – Subjects requiring hormone replacement with corticosteroids are eligible if the 
steroids are administered only for the purpose of hormonal replacement and 
at doses ≤10 mg/day of prednisone or equivalent.
 – Administration of steroids through a route known to result in a minimal 
systemic exposure (topical, intranasal, intro- ocular or inhalation) are 
acceptable.
7. Known severe hypersensitivity reactions to monoclonal antibodies (grade ≥3 
NCI- CTCAE V.4.0), any history of anaphylaxis, or uncontrolled asthma (ie, 3 or 
more features of partially controlled asthma).
8. Persisting toxicity related to prior therapy of grade >1 NCI- CTCAE V.4.0; 
however, alopecia and sensory neuropathy grade ≤2 is acceptable unless 
oxaliplatin administration is planned as part of the adjuvant treatment.
9. Pregnancy or lactation.
10. Known alcohol or drug abuse.
11. Clinically significant (ie, active) cardiovascular disease: cerebral vascular 
accident/stroke (<6 months prior to enrolment), myocardial infarction (<6 months 
prior to enrolment), unstable angina, congestive heart failure (≥New York Heart 
Association Classification Class II) or serious cardiac arrhythmia requiring 
medication.
12. Prior myocarditis.
13. Known history of immune colitis, immune pneumonitis, pulmonary fibrosis or 
other medical conditions (eg, inflammatory bowel disease, uncontrolled asthma), 
which, in the opinion of the investigator, might impair the subject’s tolerance of 
trial treatment.
14. Any psychiatric condition that would prohibit the understanding or rendering of 
informed consent.
15. Vaccination within 4 weeks of the first dose of avelumab and while on trial is 
prohibited except for administration of inactivated vaccines.
16. Other invasive malignancy within 2 years except for non- invasive malignancies 
such as cervical carcinoma in situ, non- melanomatous carcinoma of the skin or 
ductal carcinoma in situ of the breast that has/have been surgically cured.
ALT, alanine transaminase; AST, aspartate transaminase; ECOG PS, Eastern Cooperative Oncology Group performance status; NCI- CTCAE, National 
Cancer Institute Common Terminology Criteria for Adverse Events.
patients with dMMR/MSI- H and/or POLE exonuclease 
domain mutant colon cancers. Furthermore, given the 
availability of molecular markers for patient selection, 
funders of healthcare would be more likely to fund this 
treatment.
This study also provides a unique opportunity to conduct 
translational research analyses on pretreatment and post- 
treatment tumour tissue samples and blood samples from 
dMMR/MSI- H or POLE mutant CRC patients treated 
with the immune checkpoint inhibitor avelumab.
MeTHods
study design and treatment
POLEM is an open- label, multicentre, randomised, phase 
III trial comparing standard fluoropyrimidine- based 
adjuvant chemotherapy, followed by avelumab (exper-
imental arm) with standard fluoropyrimidine- based 
adjuvant chemotherapy alone (control arm) in patients 
who have undergone radical surgical resection for stage 
III dMMR/MSI- H or POLE exonuclease domain mutant 
colon cancer. Eligible patients (table 1) will be stratified 
in a 1:1 ratio for dMMR/MSI- H status and type of adju-
vant chemotherapy (ie, 24 weeks of single agent capecit-
abine chemotherapy vs 12 weeks of capecitabine, oxalip-
latin chemotherapy).
According to the statistical design, 402 patients (201 per 
arm) are to be randomised. It is expected that approxi-
mately 4000 participants will need to be screened in order 
to recruit 402 patients to the study, assuming an inci-
dence of dMMR/MSI- H of 10%–15% and an incidence 
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Figure 1 Study design of the POLEM trial. *Capecitabine chemotherapy for 24 weeks or capecitabine/oxaliplatin for 12 
weeks. dMMR, deficient mismatch repair; MSI- H, microsatellite instability high; MSS, microsatellite stable; pMMR, proficient 
mismatch repair.
of POLE mutations of 8%–10% in patients under 50 years 
of age.21 Considering the time required to obtain local 
approval and to initiate all participating centres, the study 
is expected to take up to 36 months to complete accrual.
There are no proscriptive criteria for surgical resection 
of the primary tumour in this trial. However, it is expected 
that resection of the tumour will be undertaken in the 
elective setting by a colorectal specialist surgeon.
Tumour MMR/MSI status will be routinely tested 
locally as per NICE guidelines17 either in the preoperative 
biopsy or resection specimen. Patients whose tumours are 
dMMR/MSI- H can provide consent to the main study 
and undergo the study screening procedures. If they 
are found to fulfil all eligibility criteria, then they will be 
randomised. Patients who are aged below 50 years and 
whose tumours are pMMR/MSS, will be asked to sign 
a pre- screening consent for the centralised analysis of 
POLE exonuclease domain mutations. Those who have 
tumours harbouring these mutations can sign the main 
study consent and undergo the study screening proce-
dures. If they are found to fulfil all eligibility criteria, then 
they will be randomised.
All eligible patients who are randomised will receive 
standard fluoropyrimidine- based adjuvant chemotherapy 
for 12 or 24 weeks depending on the decision of the local 
investigator. The choice of adjuvant chemotherapy (ie, 
24 weeks of single agent fluoropyrimidine chemotherapy 
or 12 weeks of doublet, oxaliplatin- based chemotherapy) 
must be declared by the investigator at study entry before 
randomisation. The adjuvant chemotherapy regimen and 
MMR/MSI status will be used as stratification factors.
At the end of adjuvant chemotherapy, patients who are 
randomised to the investigational arm will receive addi-
tional 24 weeks of treatment with avelumab (figure 1).
study objectives and endpoints
Primary endpoint
The primary endpoint is DFS at 3 years. This is defined 
as the proportion of subjects who are alive and disease 
free at 3 years. For subjects who neither progressed nor 
died, their DFS time will be censored at the last date of 
contact. The main analysis will take place once 60 events 
have occurred.
Relapse will be based on investigator reported imaging 
assessments or colonoscopy. Where a patient has neither 
progressed nor died, their DFS time will be censored at 
the last date of contact (known to be alive and relapse 
free).
Secondary endpoints
 ► Median DFS will be reported with a 95% CIs in each 
group.
 ► OS at 5 and 7 years is defined as the proportion of 
patients who are alive at 5 and 7 years, respectively. 
Patients alive at the time of analysis will be censored 
at the date of last follow- up. Analysis methods for OS 
will follow those of the primary endpoint DFS (see 
primary endpoints above).
 ► Median OS will also be reported as DFS section above.
 ► Adverse events as assessed by National Cancer Insti-
tute Common Terminology Criteria for Adverse 
Events V.4.0
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 ► Health- related quality of life based on EORTC QLQ 
C-30 and 5- level EuroQol 5 Dimensions: QLQ C-30 
will be summarised over time, as per the standard 
scoring manual, for each of the 15 domains using 
mean and SD. Statistical analysis will consist of linear 
mixed models and the mean difference between treat-
ments for each domain score will be presented.
 ► Quality- adjusted life years (QALYs).
 ► Health resource use: health resource use will be 
collected prospectively postrandomisation a health-
care services resource questionnaire designed for the 
trial.
Resource use and associated costs will be combined 
with quality- of- life data to provide a cost per QALY for 
fluoropyrimidine- based adjuvant chemotherapy, followed 
by avelumab compared with standard fluoropyrimidine- 
based adjuvant chemotherapy alone. In terms of analysis, 
Kaplan- Meier plots will be used to summarise the survival 
estimates and report the DFS rate at 3 years along with 
a 95% CIs in each group. DFS rates between groups 
will be compared using the log- rank test. In addition, 
Cox proportional hazards (PH) model (or alternative 
methods, eg, method of Klein) will be used to compare 
the DFS rates overall and at 3 years adjusting for prespec-
ified covariates. A test for non- PH will also be carried out.
The primary analysis for DFS outcome will be unad-
justed and will be based on the intention- to- treat (ITT) 
population with a sensitivity analysis in the modified ITT 
population and in the per- protocol population.
sample size calculation
The 3- year DFS rate in the control arm is expected 
to be about 75%.24 The experimental treatment 
(fluoropyrimidine- based chemotherapy followed by 
avelumab) is expected to improve the 3- year DFS rate by 
12% (to 87%), corresponding to an HR of 0.48. This effect 
size is justifiable since the population is highly enriched 
(with dMMR/MSI- H and POLE mutant patients) and 
second, a large effect size will also allow potential for cost- 
effectiveness of the experimental intervention.
Therefore, a sample size of at least 171 per group (342 
in total) is required (60 DFS events in total) to reject the 
null hypothesis of:
H0; HR=1 vs H1: HR HR≠1 with at least 80% power 
assuming a two- sided 5% type I error.
Assuming further a 15% drop- out rate (lost to follow- up 
rate) a total sample size of 402 will be required (201 per 
group in a 1:1 randomisation).
Planned recruitment
The incidence of stage III dMMR/MSI- H CRC is reported 
to be about 1753 per year in the UK (England and Scot-
land) (based on 41 112 CRC patients diagnosed in UK in 
2013 (latest figures), 23.7% of these are stage III and 18% 
of them are dMMR/MSI- H). Assume some 20% of these 
may fail screening/eligibility criteria, the pool of patients 
available for recruitment is likely to be approximately 
1500 per year.
With a target of 402 patients, assuming recruitment 
over 36 months, on average, about 11 patients per month 
are anticipated (ie, 400/36=~11/ month). At least 30 
sites are planned to be activated. Hence, on average, <1 
patient per month is required per site. Assuming that 
recruitment will not be heavily competitive as the number 
of CRC trials in this setting are few, the target sample size 
is expected to be reached.
dIsCussIon
The POLEM trial is one of two studies evaluating check-
point inhibitor drugs in the adjuvant setting in stage 
III dMMR/MSI- H colon cancer; the other being the 
US- based ATOMIC study ( ClinicalTrials. gov Identifier: 
NCT02912559). POLEM is distinct from ATOMIC in 
that it also includes POLE mutant colon cancers and has 
been designed to incorporate the recent IDEA collab-
oration trial data comparing 3 months vs 6 months 
fluoropyrimidine- based chemotherapy.25 The study 
opened in August 2018 and will be conducted in over at 
least 30 UK sites with potential for international collab-
oration. We anticipate that the findings could change 
the standard of care in this molecularly defined stage III 
colon cancer population.
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